About
Robert Fischer appears to be Dr. Robert Fischer of OMEICOS Therapeutics, a Berlin biotech company developing synthetic lipid mediators for cardiovascular, inflammatory, and mitochondrial diseases. OMEICOS identifies him as co-founder and CEO/CSO, and HTGF's 2015 financing announcement described him as Managing Director and Chief Scientific Officer. Before leading OMEICOS, the company says he worked as a clinical cardiologist at Charite - Universitaetsmedizin Berlin and conducted research with the Max Delbrueck Center for Molecular Medicine.
Areas of interest
biotechcardiovascular diseaseinflammatory diseasesmitochondrial diseasesdrug developmenttranslational medicinelipid mediators